tiprankstipranks
Trending News
More News >
Mediwound (MDWD)
NASDAQ:MDWD
Advertisement

Mediwound (MDWD) AI Stock Analysis

Compare
428 Followers

Top Page

MDWD

Mediwound

(NASDAQ:MDWD)

Rating:50Neutral
Price Target:
$20.00
▲(7.35% Upside)
Mediwound's overall stock score is driven by financial challenges and a lack of positive valuation metrics. While technical analysis shows neutral trends, the potential for future growth from clinical trials and strategic initiatives provides some optimism.
Positive Factors
Manufacturing Expansion
Management expects a 6-fold increase to their manufacturing capacity by expanding operations in Israel and planning a US-based manufacturing site with BARDA funding.
Partnership and Funding
MDWD and VCEL are expected to sign a new agreement with BARDA for NexoBrid, providing direct benefits from product procurement.
Product Development
The new agreement with BARDA can supply funding for two major development efforts: a room-temperature formulation and as a treatment for blast trauma wounds.
Negative Factors
Financial Performance
MediWound reported 1Q25 results with revenue of $4.0M, below expectations of $5.0M, though this was largely due to an NIH funding delay which is expected to be back on track.
Product Launch Delay
The launch of EscharEx in the US is delayed by one year to 3Q28 compared to prior 3Q27.
Revenue Decline
Revenue in 1Q totaled $4.0M, down from $5.0M in 1Q24 and below the Street's $5.2M.

Mediwound (MDWD) vs. SPDR S&P 500 ETF (SPY)

Mediwound Business Overview & Revenue Model

Company DescriptionMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
How the Company Makes MoneyMediwound generates revenue through the sale of its core products, primarily NexoBrid, which is marketed for the treatment of severe burns and other wounded tissues. The company also earns income from licensing agreements and collaborations with larger pharmaceutical firms, allowing it to expand its market reach and product offerings. Key revenue streams include direct sales to healthcare facilities, distribution agreements in various countries, and potential royalties from partners that utilize Mediwound's technology in their own product lines. Additionally, Mediwound may benefit from government grants and funding aimed at advancing medical innovations, further contributing to its financial performance.

Mediwound Earnings Call Summary

Earnings Call Date:May 21, 2025
(Q1-2025)
|
% Change Since: -10.73%|
Next Earnings Date:Aug 14, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook for MediWound. While there are significant advancements in clinical trials and strategic collaborations, financial metrics reveal challenges with declining revenue and increased losses. However, the strong growth in NexoBrid's adoption and the strategic initiatives for EscharEx show promise for future performance.
Q1-2025 Updates
Positive Updates
Strong Phase III Progress for EscharEx
The VALUE Phase III study for EscharEx is on track with recruitment for venous leg ulcers progressing as planned. The trial will enroll 216 patients across 40 sites in the US and Europe, with results expected to support regulatory submissions and commercial positioning.
NexoBrid Global Expansion
US adoption of NexoBrid continues to expand with a 207% year-over-year increase and a 31% sequential increase in revenue. There is high demand in Japan and Europe, with manufacturing capacity expansion underway.
Strategic Collaborations
Collaboration with major wound care companies, including Kerecis, Mölnlycke, and MIMEDX, adds significant validation to MediWound's clinical programs, particularly for EscharEx.
European Innovation Council Grant
Secured a EUR2.5 million grant component for the clinical and regulatory advancement of EscharEx for diabetic foot ulcers.
Negative Updates
Decline in Total Revenue
Total revenue for Q1 2025 was $4 million, down from $5 million in Q1 2024, primarily due to lower BARDA-funded development services revenue.
Increased Operating and Net Loss
Operating loss for the quarter was $5.2 million compared to $3.7 million in Q1 2024. Net loss was $0.7 million compared to a net loss of $9.7 million last year.
Reduced Cash Reserves
Cash, cash equivalents, and deposits decreased from $43.6 million at year-end 2024 to $38.7 million as of March 31, 2025.
Company Guidance
During the MediWound First Quarter 2025 Earnings Call, the company provided several performance metrics and guidance updates. MediWound reported a total revenue of $4 million for the first quarter, down from $5 million in Q1 2024, with a gross profit of $0.7 million, reflecting a gross margin of 19%. Research and development expenses increased to $2.9 million due to ongoing investment in the EscharEx VALUE Phase III trial. The operating loss for the quarter was $5.2 million, while the net loss was $0.7 million or $0.07 per share, significantly improved from a net loss of $9.7 million or $1.05 per share in the prior year, primarily due to non-cash financial income from warrant revaluation. As of March 31, 2025, the company held $38.7 million in cash and equivalents, using $5.1 million to fund operations during the quarter. Looking forward, the company is on track with its clinical trials and manufacturing expansions, expecting EscharEx's interim analysis by mid-2026, while anticipating commercial availability of NexoBrid from the new facility by 2026, post regulatory approvals.

Mediwound Financial Statement Overview

Summary
Mediwound faces significant financial challenges, with persistent net losses, negative free cash flow, and inconsistent revenue growth. Although the debt-to-equity ratio is manageable, negative equity and cash flow issues highlight long-term sustainability risks.
Income Statement
45
Neutral
Mediwound's income statement reveals a challenging financial position with consistent net losses. The gross profit margin has significantly declined from historical levels, indicating a struggle in maintaining profitability. The net profit margin is negative, reflecting substantial net losses. Revenue growth is inconsistent, with a recent decline after a previous increase. EBIT and EBITDA margins are also negative, showing operational inefficiencies.
Balance Sheet
50
Neutral
The balance sheet shows a moderate financial stability with a manageable debt-to-equity ratio due to relatively low total debt. However, the return on equity is negative due to consecutive net losses, impacting stockholders' equity. The equity ratio indicates a reasonable portion of assets funded by equity, but decreasing equity over time poses a risk.
Cash Flow
40
Negative
Mediwound's cash flow statement highlights negative free cash flow, indicating cash outflows exceeding inflows. The operating cash flow to net income ratio is negative, consistent with the company's losses. The free cash flow to net income ratio also reflects operational and capital expenditure challenges. Cash flow issues underline sustainability concerns.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue20.22M18.69M26.50M23.76M21.76M
Gross Profit2.63M3.58M13.16M8.77M7.54M
EBITDA-27.93M-4.89M-18.09M-11.38M-7.35M
Net Income-30.22M-6.72M-19.60M-13.55M-9.20M
Balance Sheet
Total Assets73.50M66.46M50.02M19.74M31.07M
Cash, Cash Equivalents and Short-Term Investments9.15M41.54M33.90M11.05M21.58M
Total Debt6.51M6.35M846.00K1.39M1.74M
Total Liabilities42.34M34.86M39.10M24.33M23.80M
Stockholders Equity31.15M31.59M10.91M-4.58M7.27M
Cash Flow
Free Cash Flow-19.90M-16.93M-12.44M-9.40M-7.82M
Operating Cash Flow-13.62M-10.46M-11.88M-8.92M-6.89M
Investing Cash Flow-8.40M-34.32M-481.00K3.55M17.39M
Financing Cash Flow19.39M22.92M35.76M-1.05M-629.00K

Mediwound Technical Analysis

Technical Analysis Sentiment
Negative
Last Price18.63
Price Trends
50DMA
20.03
Negative
100DMA
18.87
Negative
200DMA
18.28
Positive
Market Momentum
MACD
-0.42
Positive
RSI
41.11
Neutral
STOCH
41.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDWD, the sentiment is Negative. The current price of 18.63 is below the 20-day moving average (MA) of 19.61, below the 50-day MA of 20.03, and above the 200-day MA of 18.28, indicating a neutral trend. The MACD of -0.42 indicates Positive momentum. The RSI at 41.11 is Neutral, neither overbought nor oversold. The STOCH value of 41.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDWD.

Mediwound Risk Analysis

Mediwound disclosed 58 risk factors in its most recent earnings report. Mediwound reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Mediwound Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$224.79M-21.40%19.42%40.83%
51
Neutral
$7.35B-0.20-44.53%2.35%30.18%-1.17%
50
Neutral
$201.35M-77.92%-3.21%-51.08%
47
Neutral
$243.74M-26.77%-24.60%
41
Neutral
$200.38M-48.56%39.76%
35
Underperform
$162.58M-83.30%83.36%
33
Underperform
$167.22M-124.74%-2048.31%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MDWD
Mediwound
18.63
0.68
3.79%
LCTX
Lineage Therap
0.98
0.14
16.67%
ELDN
Eledon Pharmaceuticals
2.72
0.06
2.26%
DSGN
Design Therapeutics
4.28
0.03
0.71%
VTYX
Ventyx Biosciences
2.81
0.86
44.10%
TVGN
Tevogen Bio Holdings
0.90
0.30
50.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 30, 2025